January 02, 2026 a 01:00 pm
REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc., with its comprehensive portfolio ranging from EYLEA to Dupixent, continues to be a significant player in the pharmaceutical industry. Despite a stable production of flagship medicines, the diversification in applications could be impacted by shifting market sentiments and economic uncertainties. Understanding the analyst ratings can offer insights into the expected financial trajectory and market performance of Regeneron.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 16 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over the recent months, there is a visible trend of stabilization in the analyst sentiment with regards to Regeneron's stock. The number of strong buy recommendations has declined, while buy ratings hold a strong majority.
- December 2025 saw a reduction in Strong Buy ratings from November's 4 to 3.
- The Hold category has shown fluctuations, slightly increasing and maintaining at 8 in the latest dataset.
- Overall sentiment reveals confidence with minimal sell recommendations over the period, suggesting a neutral to positive long-term outlook.
Percentage Trends
There is a noticeable shift from more aggressive investment recommendations to more conservative stances. The favorability percentage for Strong Buys has shown a decrease while the Hold ratings have maintained a stable rate.
- From a high of 28% Strong Buy in April 2025, the figure dwindled to 12% by December 2025.
- Conversely, Hold ratings peaked at 47% in November 2024, dropping to a more balanced 22% recently.
- This suggests that the market is steadily becoming cautious with less aggressive bullish sentiment, reflecting possible investor hesitance amidst market dynamics.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-12 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-12-10 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-12-04 | Outperform | Outperform | BMO Capital |
| 2025-12-04 | Buy | Buy | Canaccord Genuity |
| 2025-12-03 | Equal Weight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-03 | Equal Weight | Overweight | Morgan Stanley |
| 2025-05-30 | Equal Weight | Overweight | Wells Fargo |
| 2025-05-14 | Buy | Neutral | Citigroup |
| 2025-02-05 | Outperform | Market Perform | Leerink Partners |
| 2025-01-16 | Neutral | Buy | UBS |
Interpretation
The market analysis suggests a mixed sentiment towards Regeneron Pharmaceuticals, Inc., with a significant prevalence of "Buy" recommendations. This reveals a moderate level of confidence among analysts, reflecting steady performance prospects. The downgrades seen might indicate a cautious approach given global economic factors, yet there is no overwhelming negative sentiment observed. The shifts to more neutral or balanced recommendations reveal an industry aligning for potential future market corrections or concerns over valuation levels.
Conclusion
In summary, Regeneron Pharmaceuticals, Inc. presents a relatively stable investment with a strong hold on buy positions, despite a dwindling number of strong buy recommendations. The diverse product pipeline and strategic partnerships bolster its market position, but analysts reflect caution with several downgrades evident over the recent months. This suggests a tempered outlook as compared to past overtly bullish ratings, perhaps preparing for market volatility or sector-specific headwinds. Investors should weigh these trends against the potential for high-reward opportunities typical for pharmaceutical innovators.